BCL-2 Inhibitor

1 . (canceled)

2 . A compound of Formula (I)

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

X is independently selected from N or CH;

p is an integer selected from 1 or 2;

v is an integer selected from 1 or 2;

m is an integer selected from 1, 2, or 3;

n is an integer selected from 0, 1, or 2;

t is an integer selected from 1 or 2;

Ring A is

wherein **2 refers to the position attached to phenyl;

Ring B is an aryl or 5- or 6-membered heteroaryl;

L 2 is a direct bond, —(CR a R b ) q —, —O—, —S—, —S(O)—, —SO 2 , —C(O)—, C(O)O—, —OC(O)—, —NR a —, —C(O)NR a —, —NR a C(O)—, —NR a C(O)O—, —NR a C(O)NR b —, —SO 2 NR a —, —NR a SO 2 —, —NR a S(O) 2 NR b —, —NR a S(O)NR b —, —C(O)NR a SO 2 —, —C(O)NR a SO—, —C(═NR a )NR b —, or cycloalkyl, wherein q is a number of 1 to 7;

R 11 is —C 3-10 cycloalkyl, aryl, 5- or 6-membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents R 11X ,

R 11X , at each occurrence, is independently halogen, —C 1-8 alkyl, haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, —CN, —NO 2 , —OR 11a , —SO 2 R 11a , —COR 11a , —CO 2 R 11a , —CONR 11a R 11b , —C(═NR 11a )NR 11b R 11c , —NR 11a R 11b , —NR 11a COR 11b , —NR 11a CONR 11b R 11c , —NR 11a CO 2 R 11b , —NR 1a SONR 11b R 11c , —NR 11a SO 2 NR 11b R 11c , —P(═O)R 11a R 11b , or —NR 11a SO 2 R 11b wherein said C 3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 1-8 alkoxyl, or -haloC 1-8 alkoxyl;

R 11a , R 11b and R 11c are each independently hydrogen, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C 3-8 cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 1-8 alkoxyl, or -haloC 1-8 alkoxyl;

R 12 is hydrogen, halogen, —C 1-8 alkyl, haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, —C 3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, -oxo, —CN, —NO 2 , —OR 1a , —SO 2 R 1a , —COR 1a , —CO 2 R 1a , —CONR 1a R 1b , —C(═NR 1a )NR 1b R 1c , —NR 1a R 1b , —NR 1a COR 1b , —NR 1a CONR 1b R 1c , —NR 1a CO 2 R 1b , —NR 1a SONR 1b R 1c , —NR 1a SO 2 NR 1b R 1c , or —NR 1a SO 2 R 1b ;

R 1a and R 1b , are each independently hydrogen, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R 1c is hydrogen, —C 1-8 alkyl, -haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R 2 is independently selected from halogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl or —C 3-6 cycloalkyl; wherein said —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl or —C 3-6 cycloalkyl are each independently optionally substituted with halogen, hydroxy, C 1-6 alkoxy, or amino, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 3-6 cycloalkyl or C 3-6 heterocyclyl;

R 3 is -L 1 -CyC,

wherein

L 1 is a direct bond, —(CR a R b ) 1-4 —, —O—(CR a R b ) 0-3 —, —NH—(CR a R b ) 1-3 , —NHC(O)NR a —(CR a R b ) 1-3 , or —NH—;

CyC is cycloalkyl, or heterocyclyl, each of which is optionally substituted with one, two, three or four substituents R 3a ;

R 3a is independently selected from hydrogen, halogen, cyano, oxo, —OR 3b , —NR 3b R 3c , —COR 3b , —SO 2 R 3b , —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, -cycloalkyl, or heterocyclyl, each of said —C 1-8 alkyl, and heterocyclyl is optionally substituted with one, or two substituents R 3e , which is selected from hydrogen, halogen, cyano, —OR 3f , —C 1-8 alkyl, -cycloalkyl, or heterocyclyl;

wherein R 3b , and R 3c are each independently hydrogen, —C 1-8 alkyl, -cycloalkyl, or heterocyclyl, said —C 1-8 alkyl is optionally substituted with one or two substituents R 5e , which is hydrogen, —NR 3f R 3g , -cycloalkyl, or heterocyclyl;

R 3f and R 3g are each independently hydrogen or —C 1-8 alkyl;

or, two adjacent R 3 on the phenyl ring together with the phenyl ring form a benzo ring, said ring is optionally substituted with heteroaryl;

R a and R b are independently hydrogen, —C 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and,

R 4 and R 5 are each independently hydrogen, halogen, cyano, —NO 2 , —C 1-8 alkyl, —C 2-8 alkenyl, or —C 2-8 alkynyl.

3 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

X is N;

ring B is phenyl, furanyl, isoxazolyl, pyridinyl, pyrazolyl, or pyrimidinyl;

R 2 is halo, —C 1-6 alkyl or —C 3-4 cycloalkyl; wherein said —C 1-6 alkyl and —C 3-4 cycloalkyl are each independently optionally substituted with hydrogen, —C 1-3 alkyl, C 3-6 cycloalkyl or C 3-6 heterocyclyl;

n is 0; and

L 2 is —(CH 2 ) q —, or —O—, wherein q is an integer from 1-3.

4 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 2 is fluoro, methyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl or morpholinomethyl.

5 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 11 is —C 3-10 cycloalkyl, aryl, 5- or 6-membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, or 3 substituents R 11X .

6 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

a) R 11 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 3- to 6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from oxygen and nitrogen atoms; or

b) R 11 is selected from cyclohexyl, bicyclo[1.1.1]pentanyl, tetrahydro-2H-pyran-1-yl, tetrahydro-2-H-pyran-2-yl, tetrahydro-2-H-pyran-3-yl, tetrahydro-2-H-pyran-4-yl oxazol-2-yl, oxazol-4-ylmethyl or oxazol-5-yl; or

c) R 11 is selected from phenyl or 8- to 10-membered bicyclic aryl, optionally substituted with 1 to 2 substituents R 11X ; or

d) R 11 is cyclohexyl, 4-methoxylcyclohexyl, bicyclo[1.1.1]pentan-1-yl, tetrahydro-2H-pyran-4-yl, oxazol-4-yl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 4-cyanophenyl, 4-methylphenyl, 4-(trifluoromethyl)phenyl, 2-methoxylphenyl, 3-methoxylphenyl, 4-methoxylphenyl, 4-ethoxylphenyl, 4-methoxylphenyl, 4-(trifluoromethoxyl)phenyl, 2,4-dimethoxylphenyl, 2,3-dimethoxylphenyl, 3,4-dimethoxylphenyl, 3,5-dimethoxylphenyl, 3,4,5-trimethoxylphenyl, chroman-6-yl, chroman-4-yl, 2,3-dihydrobenzo[b][1,4]dioxin-6-yl, 2,3-dihydrobenzo[b][1,4]dioxin-5-yl, or 5,6,7,8-tetrahydronaphthalen-2-yl, or 5,6,7,8-tetrahydronaphthalen-1-yl; or

e) R 11 is furanyl, isoxazolyl, pyridinyl, pyrazolyl, pyrimidinyl, benzo[b]thiophenyl or benzofuranyl; or

f) R 11 -L 2 - is selected from furan-2-ylmethyl, isoxazol-4-ylmethyl, (pyridin-3-yl))methyl, (6-methoxypyridin-3-yl)methyl, (5-methoxypyridin-2-yl)methyl, (1-methyl-1H-pyrazol-4-yl)methyl, (3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl, (1-cyclopropyl-1H-pyrazol-4-yl)methyl, (5-methoxypyrimidin-2-yl)methyl, benzo[b]thiophen-5-ylmethyl, benzo[b]thiophen-4-ylmethyl, benzofuran-5-ylmethyl, or benzofuran-4-ylmethyl.

7 . The compound of claim 6 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

i) R 11 is chromanyl, benzo[b][1,4]dioxinyl,5,6,7,8-tetrahydronaphthalenyl, octahydro-5H-2,5-methanoindenyl, 2,3,4,5-tetrahydrobenzo[b]oxepinyl, or adamantanyl, each of which is optionally substituted with 1 or 2 R 11X ; or

ii) R 11 is furan-2-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-2-yl, 1H1-pyrazol-4-yl, pyrimidin-2-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-4-yl, benzofuran-5-yl, or benzofuran-4-yl; or

iii) R 11 is phenyl substituted with cyano, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, difluoromethyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetan-3-yl, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, —NH 2 , or —NH(CH 3 ).

8 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 11X is halogen, cyano, hydroxy, —C 1-8 alkyl, haloC 1-8 alkyl, —C 2-8 alkenyl, —C 2-8 alkynyl, C 1-6 alkoxyl, haloC 1-6 alkoxyl, C 3-6 cycloalkyl, heterocyclyl, C 3-6 cycloalkoxyl, —NH 2 , —NH(C 1-8 alkyl), —N(C 1-8 alkyl) 2 or heterocyclyl-O—.

9 . The compound of claim 5 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

a) R 11 -L 2 - is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1,2,3,4-tetrahydronaphthalen-1-yl, 3-phenylcyclobut-1-yl, 3-phenylcyclopent-1-yl, 4-phenylcyclohex-1-yl or 3-(4-methoxylphenyl)cyclopent-1-yl; or

b) R 11 -L 2 - is a 3- to 6-membered monocyclic heterocyclyl selected from oxetanyl, tetrahydrofuranyl, or tetrahydro-2H-pyranyl.

10 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L 2 is —SO 2 — or —CO—, and R 11 is phenyl, which is optionally substituted with C 1-3 alkoxyl.

11 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein m is 1, R 3 is -L 1 -CyC, and L 1 is a direct bond, —(CH 2 ) 0-2 —, —N(CH 2 ) 0-2 , or —O(CH 2 ) 0-2 .

12 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

a) CyC is cycloalkyl selected from monocyclic C 3-8 cycloalkyl or bridged cycloalkyl, each of which is optionally substituted with one or two substituents R 3a ; or

b) CyC is heterocyclyl selected from monocyclic 4 to 9-membered heterocyclyl containing one nitrogen, oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9-membered heterocyclyl containing two heteroatoms selected from oxygen, sulfur, or nitrogen as ring members, each of which is optionally substituted with one, two, three or four substituents R 3a ; or

c) CyC is 5- to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, or oxygen as ring members, each of which is optionally substituted with one, two, three or four substituents R 3a ; or

d) CyC is 5- to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, each of which is optionally substituted with one, two, three or four substituents R 3a ; or

e) CyC is a monocyclic 6-membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members; or

f) CyC is 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.

13 . The compound of claim 12 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

i) CyC is cyclobutyl, cyclopentyl or cyclohexyl, each of which is optionally substituted with one or two substituents R 3a ; or

ii) CyC is monocyclic 4 to 6-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members; or

iii) CyC is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperdinyl; or

iv) CyC is dioxanyl, morpholino, morpholinyl, or piperizinyl; or

v) CyC is 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.

14 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein CyC is selected from oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperdin-4-yl, piperdin-2-yl, and piperdin-3-yl.

15 . The compound of claim 12 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein CyC is

(7-oxa-2-azaspiro[3.5]nonan-2-yl), or

(2-oxaspiro[3.5]nonan-7-yl), each of which is optionally substituted with one, two, three or four substituents R 3a .

16 . The compound of claim 15 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 3a is independently selected from hydrogen, halogen, cyano, oxo, —OR 3b , —NR 3b R 3c , —C(═O)R 3b , —SO 2 R 3b , —C 1-6 alkyl, monocyclic C 3-6 cycloalkyl, or monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members, each of said —C 1-6 alkyl and monocyclic 4 to 9-membered heterocyclyl group is optionally substituted with one or two substituents R 3e .

17 . The compound of claim 16 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein:

a) monocyclic C 3-6 cycloalkyl as R 3a is cyclopropyl; or

b) monocyclic 4 to 9-membered heterocyclyl as R 3a is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

c) monocyclic 4 to 9-membered heterocyclyl as R 3a is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperizinyl, or morpholinyl; or

d) monocyclic 4 to 9-membered heterocyclyl as R 3a is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morphin-4-yl; or

e) heterocyclyl as R 3e is monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

f) heterocyclyl as R 3e is tetrahydro-pyran-4-yl; or

g) R 3a is —NR 3b R 3c , wherein R 3b is hydrogen, and R 3c is heterocyclyl; or

h) R 3a is —NR 3b R 3c , wherein R 3b is hydrogen, and R 3c is tetrahydro-pyran-4-yl; or

i) R 3a is —NR 3b R 3 , wherein R 3b and R 3a are each independently hydrogen or —C 1-6 alkyl substituted with cycloalkyl; or

j) R 3a is —OR 3b or —SO 2 R 3b , wherein R 3b is hydrogen or C 1-8 alkyl; or

k) R 3a is —COR 3b , wherein R 3b is hydrogen or C 1-6 alkyl optionally substituted with —NR 3f R 3g , wherein R 3f and R 3g are each independently hydrogen or C 1-6 alkyl.

18 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein two adjacent R 3 on the phenyl ring together with the phenyl ring form indazolyl which is substituted with tetrahydropyranyl.

19 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein m is 1 and R 3 is:

20 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 4 is fluoro (—F), chloro (—Cl) or bromo (—Br).

21 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R 4 is at position 3 of the pyrrolo[2,3-b]pyridin-5-yl ring.

22 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound is selected from

23 . A pharmaceutical composition, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and at least one pharmaceutically acceptable excipient.